FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947995747> ?p ?o ?g. }

• W2947995747 abstract "Osteoarthritis (OA) is a degenerative joint disease that causes pain and bone deterioration driven by an increase in prostaglandins (PGs) and inflammatory cytokines. Current treatments focus on inhibiting prostaglandin production, a pro-inflammatory lipid metabolite, with NSAID drugs; however, other lipid signaling targets could provide safer and more effective treatment strategies. Epoxides of polyunsaturated fatty acids (PUFAs) are anti-inflammatory lipid mediators that are rapidly metabolized by the soluble epoxide hydrolase (sEH) into corresponding vicinal diols. Interestingly, diol levels are increased in the synovial fluid of humans with OA, warranting further research on the biological role of this lipid pathway in the progression of OA. sEH inhibitors (sEHI) stabilize these biologically active, anti-inflammatory lipid epoxides, resulting in analgesia in both neuropathic, and inflammatory pain conditions. Most experimental studies testing the analgesic effects of sEH inhibitors have used experimental rodent models, which do not completely represent the complex etiology of painful diseases. Here, we tested the efficacy of sEHI in aged dogs with natural arthritis to provide a better representation of the clinical manifestations of pain. Two sEHI were administered orally, once daily for 5 days to dogs with naturally occurring arthritis to assess efficacy and pharmacokinetics. Blinded technicians recorded the behavior of the arthritic dogs based on pre-determined criteria to assess pain and function. After 5 days, EC1728 significantly reduced pain at a dose of 5 mg/kg compared to vehicle controls. Pharmacokinetic evaluation showed concentrations exceeding the enzyme potency in both plasma and synovial fluid. In vitro data showed that epoxyeicosatrienoic acid (EETs), epoxide metabolites of arachidonic acid, decreased inflammatory cytokines, IL-6 and TNF-α, and reduced cytotoxicity in canine chondrocytes challenged with IL1β to simulate an arthritic environment. These results provide the first example of altering lipid epoxides as a therapeutic target for OA potentially acting by protecting chondrocytes from inflammatory induced cytotoxicity. Considering the challenges and high variability of naturally occurring disease in aged dogs, these data provide initial proof of concept justification that inhibiting the sEH is a non-NSAID, non-opioid, disease altering strategy for treating OA, and warrants further investigation." @default.
• W2947995747 created "2019-06-07" @default.
• W2947995747 creator A5013909385 @default.
• W2947995747 creator A5026538320 @default.
• W2947995747 creator A5031532167 @default.
• W2947995747 creator A5050186341 @default.
• W2947995747 creator A5054061818 @default.
• W2947995747 creator A5065564993 @default.
• W2947995747 creator A5066735935 @default.
• W2947995747 creator A5070977934 @default.
• W2947995747 creator A5089026355 @default.
• W2947995747 date "2019-05-31" @default.
• W2947995747 modified "2023-10-16" @default.
• W2947995747 title "Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine Osteoarthritis" @default.
• W2947995747 cites W148367253 @default.
• W2947995747 cites W1505044896 @default.
• W2947995747 cites W1569643828 @default.
• W2947995747 cites W1794964189 @default.
• W2947995747 cites W1944307883 @default.
• W2947995747 cites W1982462615 @default.
• W2947995747 cites W1992303064 @default.
• W2947995747 cites W2018319340 @default.
• W2947995747 cites W2038773696 @default.
• W2947995747 cites W2038810948 @default.
• W2947995747 cites W2039332805 @default.
• W2947995747 cites W2096746754 @default.
• W2947995747 cites W2097927167 @default.
• W2947995747 cites W2108661128 @default.
• W2947995747 cites W2115197899 @default.
• W2947995747 cites W2120014586 @default.
• W2947995747 cites W2120276871 @default.
• W2947995747 cites W2142219464 @default.
• W2947995747 cites W2145630011 @default.
• W2947995747 cites W2147830477 @default.
• W2947995747 cites W2154385453 @default.
• W2947995747 cites W2163522693 @default.
• W2947995747 cites W2171324043 @default.
• W2947995747 cites W2204551059 @default.
• W2947995747 cites W2299367339 @default.
• W2947995747 cites W2314044888 @default.
• W2947995747 cites W2331696434 @default.
• W2947995747 cites W2417725630 @default.
• W2947995747 cites W2471713672 @default.
• W2947995747 cites W2530059597 @default.
• W2947995747 cites W2593626446 @default.
• W2947995747 cites W2610502227 @default.
• W2947995747 cites W2615216250 @default.
• W2947995747 cites W2664285537 @default.
• W2947995747 cites W2723007231 @default.
• W2947995747 cites W2746227110 @default.
• W2947995747 cites W2790313400 @default.
• W2947995747 cites W2870006450 @default.
• W2947995747 cites W2898229478 @default.
• W2947995747 cites W4241354719 @default.
• W2947995747 cites W4245966879 @default.
• W2947995747 doi "https://doi.org/10.3389/fphar.2019.00533" @default.
• W2947995747 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6554663" @default.
• W2947995747 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31214021" @default.
• W2947995747 hasPublicationYear "2019" @default.
• W2947995747 type Work @default.
• W2947995747 sameAs 2947995747 @default.
• W2947995747 citedByCount "29" @default.
• W2947995747 countsByYear W29479957472019 @default.
• W2947995747 countsByYear W29479957472020 @default.
• W2947995747 countsByYear W29479957472021 @default.
• W2947995747 countsByYear W29479957472022 @default.
• W2947995747 countsByYear W29479957472023 @default.
• W2947995747 crossrefType "journal-article" @default.
• W2947995747 hasAuthorship W2947995747A5013909385 @default.
• W2947995747 hasAuthorship W2947995747A5026538320 @default.
• W2947995747 hasAuthorship W2947995747A5031532167 @default.
• W2947995747 hasAuthorship W2947995747A5050186341 @default.
• W2947995747 hasAuthorship W2947995747A5054061818 @default.
• W2947995747 hasAuthorship W2947995747A5065564993 @default.
• W2947995747 hasAuthorship W2947995747A5066735935 @default.
• W2947995747 hasAuthorship W2947995747A5070977934 @default.
• W2947995747 hasAuthorship W2947995747A5089026355 @default.
• W2947995747 hasBestOaLocation W29479957471 @default.
• W2947995747 hasConcept C112705442 @default.
• W2947995747 hasConcept C126322002 @default.
• W2947995747 hasConcept C142724271 @default.
• W2947995747 hasConcept C181199279 @default.
• W2947995747 hasConcept C185592680 @default.
• W2947995747 hasConcept C18605011 @default.
• W2947995747 hasConcept C204787440 @default.
• W2947995747 hasConcept C2776164576 @default.
• W2947995747 hasConcept C2776268809 @default.
• W2947995747 hasConcept C2776352991 @default.
• W2947995747 hasConcept C2777077863 @default.
• W2947995747 hasConcept C2777477808 @default.
• W2947995747 hasConcept C2778078955 @default.
• W2947995747 hasConcept C2780820201 @default.
• W2947995747 hasConcept C55493867 @default.
• W2947995747 hasConcept C71924100 @default.
• W2947995747 hasConcept C98274493 @default.
• W2947995747 hasConceptScore W2947995747C112705442 @default.
• W2947995747 hasConceptScore W2947995747C126322002 @default.
• W2947995747 hasConceptScore W2947995747C142724271 @default.
• W2947995747 hasConceptScore W2947995747C181199279 @default.
• W2947995747 hasConceptScore W2947995747C185592680 @default.

• next